Transcript of the earnings call held on 17 July 2026 post announcement of the financial results of the Company for the quarter ended 30 June 2026.
AI summary
- Q1 FY27 revenue 1,671mn INR +43% y-y, EBITDA 323mn INR +86% y-y
- Phase Transfer Catalysts revenue 428mn INR +38% q-q; growth driven by wider industry adoption
- Structure Directing Agents demand strong; Euro 7 implementation driving growth
- Electrolyte Salts revenue impacted by raw material shortages; hybrid battery commercialization progressing
- Pharma & Agro Intermediates revenue 584mn INR +63% q-q; new pharma molecules commercializing
- Semiconductor product qualified; commercial scale batch delivered; large opportunity expected
- Board approved 200cr INR greenfield capex for multiproduct facility; revenue target 300cr INR at peak
- FY27 revenue growth guidance 25-30%; EBITDA margin guidance 20-22%
- Continuous flow chemistry adoption expanding; 7-8 products in pilot/commercial phase
- Semiconductor commercialization expected post Q4 FY28; patience required for scale-up
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 TATVA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add TATVA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Tatva Chintan Pharma Chem Limited
Important.
The summary above is generated automatically from Tatva Chintan Pharma Chem Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.